Seema Malkani
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Neuroscience and Neuropharmacology Research, Alzheimer's disease research and treatments, Memory and Neural Mechanisms, Neuroinflammation and Neurodegeneration Mechanisms, Diabetes Treatment and Management
Most-Cited Works
- → Loss of Presenilin Function Causes Impairments of Memory and Synaptic Plasticity Followed by Age-Dependent Neurodegeneration(2004)760 cited
- → Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides(2004)557 cited
- → Gene delivery of human apolipoprotein E alters brain Aβ burden in a mouse model of Alzheimer's disease(2005)199 cited
- → Conditional Inactivation of Presenilin 1 Prevents Amyloid Accumulation and Temporarily Rescues Contextual and Spatial Working Memory Impairments in Amyloid Precursor Protein Transgenic Mice(2005)153 cited
- → An egr-1 (zif268) Antisense OligodeoxynucleotideInfused Into the Amygdala Disrupts Fear Conditioning(2004)105 cited
- → Induction of NGFI-B mRNA following contextual fear conditioning and its blockade by diazepam(2000)45 cited
- → Differential expression of EGR-1 mRNA in the amygdala following diazepam in contextual fear conditioning(2000)44 cited
- → Individualized HbA1c Goals, and Patient Awareness and Attainment of Goals in Type 2 Diabetes Mellitus: A Real-World Multinational Survey(2021)24 cited
- → Chapter 4.7 A neurobehavioral system approach in rats to study the molecular biology of fear(1999)3 cited
- → Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity(2023)2 cited